Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda

Diarrhoea Clinical Trial

Official title:

A Randomised Controlled Trial in HIV-1 Exposed Ugandan Infants to Estimate Additional Benefits (Non-specific Effects) of BCG

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02606526
• Other study ID #: 2015-114
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 2016
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: Makerere University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis. Though the available literature is mostly from observational study designs, and is fraught with controversy, BCG vaccination at birth, in a high risk population of HIV exposed children, may protect infants against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy, when the immune system is more mature, may offer even greater protection. The appropriate timing of BCG vaccination could therefore be up for revision. This study will therefore compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV exposed (HE) babies. Methods: This is an individually randomized clinical trial in 4,500 HIV exposed infants. The intervention is an intra-dermal administration of 0.05 ml of BCG vaccine within 24 hours of birth while the comparator will be an intra-dermal administration of 0.05ml of BCG vaccine at 14 weeks of age. The main study outcomes include: 1. Severe illness in the first 14 weeks of life, 2. Innate and adaptive immune responses to mycobacterial, non-mycobacterial antigens and TLR-agonists 3. Severe illness in the first 14-52 weeks and 0-52 weeks of life. The study will be carried in two health centers and one district hospital in Uganda. Implications: A well-timed BCG vaccination could have important additional benefits in HE infants. This trial could inform the development of programmatically appropriate timing of BCG vaccination for HE infants.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4500
• Est. completion date: December 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 1 Day

Eligibility

Inclusion Criteria:

A baby born at a participating study clinic will be included if s/he:

1. has a mother with a positive HIV test (ELISA or rapid test)

2. is receiving peri-exposure prophylaxis as part of the standard/national guidelines in Uganda

3. has a mother that is of legal age for participation in clinical research studies in Uganda or is an emancipated minor

4. has a mother/caregiver that resides within the study area, is not intending to move out of the area in the next 4 months and is likely to be traceable for up to 12 months

5. has a mother/caregiver that gives informed consent to random assignment to either of the two trial arms

6. has a mother that has received antiretroviral therapy (ART) for at least 4 weeks Exclusion Criteria:

A new-born child will be excluded if she/he has:

1. an identified serious congenital malformation(s)

2. severe illness requiring hospitalization

3. a birth weight < 2.0 kg

4. a mother participating in another clinical trial on the day of enrolment or a mother who will participate in another clinical trial within the next month.

5. a mother or other household member with symptoms and signs of tuberculosis on the day of enrolment

6. a severely ill mother with (a) condition(s) requiring hospitalization

7. a baby with an Apgar score at 5 minutes <7

8. a twin or triplet

Related Conditions & MeSH terms

• Diarrhea
• Diarrhoea
• Lower Respiratory Infection
• Respiratory Tract Infections
• Sepsis
• Septicaemia
• Severe Illness

Intervention

Biological:
• BCG at birth
See previous description
• Control arm: Delayed BCG
See previous description

Locations

Country	Name	City	State
Uganda	Health Centers in Mukono and Kampala districts	Kampala

Sponsors (3)

Lead Sponsor	Collaborator
Makerere University	Radboud University Medical Center, University of Bergen

Country where clinical trial is conducted

Uganda, 

References & Publications (2)

Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskar T, Sommerfelt H; PROMISE- EBF Study Group. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health. 2015 Feb 22;15:175. doi: 10.1186/s12889-015-1497-8. — View Citation

Nankabirwa V, Tumwine JK, Namugga O, Tylleskar T, Ndeezi G, Robberstad B, Netea MG, Sommerfelt H. Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial. Trials. 2017 Mar 31;18(1):152. doi: 10.1186/s13063-017-1881-z. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severe illness	Among children <2 months of age, severe illness (other than TB) will be defined as an acute illness that is associated with any of the following danger signs observed or verified by a clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of =38.0 deg C or <35.5 deg C, grunting, cyanosis, convulsions or a history of convulsions (except epilepsy), and/or requires hospitalization and/or results in death. Among children =2 months of age, severe illness (other than TB) will be defined as an acute illness that is associated with at least one of the following danger signs observed by a clinician: inability to drink or breastfeed lethargy or unconsciousness, vomiting of all feeds, convulsions or a history of convulsions (except epilepsy), and/or requires hospitalization and/or results in death. Events resulting from violent injury or burns are not considered severe illness.	The first 14 weeks of life
Primary	Innate and adaptive immune responses against mycobacterial and non-mycobacterial antigens.	The following immunological outcomes will be measured in a sub-sample of 180 infants: Innate immune responses (IL-6, TNF, IL-10, IL-1b) against TLR-agonists and adaptive immune responses (IFNy, IL-17, IL-10 and IL-22) against mycobacterial (ESAT-6/CFT10 and PPD) and non-mycobacterial antigens (C.albicans, S. aureus and SARS-CoV-2 spike peptides).	14 weeks post BCG vaccination
Secondary	Severe illness from 48 h after randomization to 14 weeks of life	Severe illness as defined for primary outcome 1	48 hours to 14 weeks of life
Secondary	Severe illness in weeks 0-52 and 14-52 of life	Severe illness as defined for primary outcome 1	First 0-52 and 14-52 weeks of life
Secondary	Adverse events	Axillary and cervical lymphadenopathy	First 52 weeks of life
Secondary	Infant death	Death during the first year of life	First year of life
Secondary	BCG scar at 52 weeks of age	Presence or absence of a BCG scar at the vaccination site	First year of life
Secondary	Growth up to 52 weeks of life	Growth measured by weight and length	First year of life
Secondary	Severe illness until 6 weeks of age	Severe illness as defined for primary outcome 1	6 weeks
Secondary	Severe illness until 14 weeks of age within strata of presence or absence of maternal BCG scar	In addition to the above-mentioned outcomes, an analysis plan will be developed which may include any necessary new or modifications in the current secondary outcomes and describe any new secondary analyses, including for sub-group effects".	14 weeks

External Links

•   Related Info